MicroRNA-155 Promotes Autoimmune Inflammation by Enhancing Inflammatory T Cell Development

Ryan M. O'Connell, Daniel Kahn, William S.J. Gibson, June L. Round, Rebecca L. Scholz, Aadel A. Chaudhuri, Melissa E. Kahn, Dinesh S. Rao, and David Baltimore

1Division of Biology, California Institute of Technology, 330 Braun, 1200 E. California Boulevard, Pasadena, CA 91125, USA
2Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine
3Department of Pathology and Laboratory Medicine
David Geffen School of Medicine, University of California at Los Angeles, 10833 Le Conte Ave., Los Angeles, CA 90095, USA
4Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
*Correspondence: baltimo@caltech.edu
DOI 10.1016/j.immuni.2010.09.009

SUMMARY

Mammalian noncoding microRNAs (miRNAs) are a class of gene regulators that have been linked to immune system function. Here, we have investigated the role of miR-155 during an autoimmune inflammatory disease. Consistent with a positive role for miR-155 in mediating inflammatory responses, Mir155−/− mice were highly resistant to experimental autoimmune encephalomyelitis (EAE). miR-155 functions in the hematopoietic compartment to promote the development of inflammatory T cells including the T helper 17 (Th17) cell and Th11 cell subsets. Furthermore, the major contribution of miR-155 to EAE was CD4+ T cell intrinsic, whereas miR-155 was also required for optimum dendritic cell production of cytokines that promoted Th17 cell formation. Our study shows that one aspect of miR-155 function is the promotion of T cell-dependent tissue inflammation, suggesting that miR-155 might be a promising therapeutic target for the treatment of autoimmune disorders.

INTRODUCTION

The mammalian inflammatory response has evolved to control infection by microbial pathogens before the onset of sepsis and death, while also playing important roles in tissue repair (Medzhitov, 2008). Despite its utility, when the inflammatory response is activated inappropriately, it may be directed against specific self-tissue antigens and cause serious disease. The outcome can be debilitating to important organ systems and is the underlying cause of widespread human autoimmune disorders.

Recent work has revealed that IL-17-producing inflammatory CD4+ T cells, or T helper 17 (Th17) cells, are critical mediators of chronic, autoimmune inflammation (Bettelli et al., 2006; Ivanov et al., 2006). Th17 cell development is driven by cytokines produced primarily by cells of the innate immune system, including transforming growth factor-β (TGF-β), interleukin-6 (IL-6), IL-23, and IL-1 (Bettelli et al., 2006; Langrish et al., 2005; Veldhoen et al., 2006). The impact of Th17 cells was first made evident in mice, where overexpression of IL-17 led to increased granulopoiesis in vivo (Schwarzenberger et al., 1998). Subsequent studies demonstrated that inhibition of IL-17 in mice can ameliorate several autoimmune disorders including experimental autoimmune encephalomyelitis (EAE), collagen-induced arthritis (CIA), and inflammatory bowel disease (IBD) (Ivanov et al., 2006; Komiyama et al., 2006; Murphy et al., 2003).

Micro-RNAs (miRNAs) are a class of noncoding RNAs that modulate gene expression at the posttranscriptional level and are involved in regulating several aspects of inflammation (O’Connell et al., 2010; Xiao and Rajewsky, 2009). Specific miRNAs, such as miR-146a, miR-155, and miR-132, were initially shown to be upregulated during the macrophage inflammatory response (O’Connell et al., 2007; Taganov et al., 2006). The functional impact of certain miRNAs on inflammation has been demonstrated in vivo. Mice deficient in miR-223, a miRNA that is enriched in myeloid cells, display elevated granulocyte numbers and increased immunity against fungi (Johnnidis et al., 2008). Other studies have found important roles for miRNAs in lymphocytes. For instance, enforced expression of the miR-17-92 cluster in T cells or specific deletion of Dicer in T regulatory (Treg) cells both trigger lethal autoimmune conditions (Chong et al., 2008; Liston et al., 2008; Xiao et al., 2008; Zhou et al., 2008).

miR-155 was among the first miRNAs linked to inflammation by virtue of its potent upregulation in multiple immune cell lineages by Toll-like receptor (TLR) ligands, inflammatory cytokines, and specific antigens (Haasch et al., 2002; O’Connell et al., 2007; Taganov et al., 2006; Thai et al., 2007). A wide variety of immunologically relevant targets of miR-155 have been reported, implying distinct roles in mammalian immunity. Among these roles, miR-155 has been shown to be important for immunoglobulin (Ig) class switching to IgG in B cells via targeted repression of activation-induced cytidine deaminase (AID) and the transcription factor PU.1 (Dorsett et al., 2008; Rodríguez et al., 2007; Thai et al., 2007; Vigorito et al., 2007). The fitness of T regulatory cells is influenced by direct repression of suppressor of cytokine signaling 1 (SOCS1) by miR-155 (Lu et al., 2009). In myeloid cells, overexpression of miR-155 drives a myeloproliferative disorder through a mechanism involving reduced src homology 2 domain-containing inositol-5-phosphatase 1 (SHIP1) expression, suggesting that...
miR-155 is acting as a positive regulator of inflammation (O’Connell et al., 2008, 2009). Despite these reported functions of miR-155 in both innate and adaptive immune cells, to date there has been little genetic evidence that endogenously expressed miR-155 actually impacts inflammatory responses in vivo. In the present study, we investigated the role that miR-155 might play during antigen-specific inflammatory responses against self-tissues.

**RESULTS**

**Mir155**<sup>−/−</sup> Mice Are Resistant to EAE Induced by Myelin Oligodendrocyte Glycoprotein<sub>35-55</sub>

To identify a possible role for miR-155 in mediating tissue-specific autoimmune inflammation, a mouse model of EAE was used. Both wild-type (WT) and Mir155<sup>−/−</sup> mice were immunized with 100 μg of the myelin oligodendrocyte glycoprotein (MOG) peptide<sub>35-55</sub> emulsified in complete Freund’s adjuvant (CFA) followed by administration of pertussis toxin. As anticipated, WT mice first displayed neurologic symptoms approximately 9 days postimmunization, with peak disease severity on day 14 (average clinical score of 2.1) and 100% disease incidence (Figures 1A and 1B). In contrast, Mir155<sup>−/−</sup> mice exhibited a later onset of symptoms on day 11, with a low peak disease severity on day 15 (average clinical score of 0.3). Unlike the WT controls, the disease incidence in Mir155<sup>−/−</sup> mice was only 60% (Figures 1A and 1B). On day 25, mice were sacrificed and underwent further evaluation including tissue histological analysis. Hema- toxylin and eosin (H&E) brain cross-sections were scored for disease severity (Figures 1C and 1D). As expected, WT mice suffered from heavy perivascular congestion, parenchymal infiltration, and focal meningeal lymphocytosis. However, brain tissue from Mir155<sup>−/−</sup> mice showed minimal histologic evidence of inflammation consistent with the mild clinical manifestation of EAE (Figures 1C and 1D). Furthermore, upon analyzing the draining lymph nodes (LNs) and spleens from both groups of mice, we found decreased overall cellularity in LNs from Mir155<sup>−/−</sup> mice and compositionally fewer CD11b<sup>+</sup> myeloid cells in Mir155<sup>−/−</sup> spleens (Figures 1E and 1F). Both of these observations are consistent with a reduced inflammatory condition in Mir155<sup>−/−</sup> mice.

Lethally irradiated WT C57BL/6 mice were next reconstituted with either Mir155<sup>+/+</sup> or Mir155<sup>−/−</sup> bone marrow (BM) cells. After 4 months, proper engraftment and localization of the miR-155 deficiency to the hematopoietic compartment was confirmed by assaying miR-155 amounts in activated splenic B cells (Figure 1G). After induction of EAE, mice with Mir155<sup>+/+</sup> hematopoietic cells exhibited a faster and more severe disease phenotype than mice containing Mir155<sup>−/−</sup> hematopoietic cells (Figure 1H). In a separate experiment, 25 x 10<sup>5</sup> WT encephalitogenic splenocytes from day 12 EAE WT mice were transferred into WT or Mir155<sup>−/−</sup> hosts, which were monitored for the presence of clinical symptoms. Both groups began to show symptoms by day 8 postadoptive transfer and had comparable disease scores throughout the 22 day time course (Figure 1I). Furthermore, both cohorts had a disease incidence of 100% (Figure S1 available online). Taken together, these data demonstrate that miR-155 functions in the hematopoietic compartment to promote EAE.

**Mir155**<sup>−/−</sup> Mice Exhibit Defective Inflammatory T Cell Development during EAE

Th17 and Th1 cells are hematopoietic cells that develop during tissue-specific inflammatory responses and play a pivotal role in enhancing inflammation (Littman and Rudensky, 2010). Therefore, we examined lymph nodes (LNs) and splenocytes from WT and Mir155<sup>−/−</sup> mice for the presence of IL-17 (Th17)- or interferon-γ (IFN-γ) (Th1)-producing CD4<sup>+</sup> T cells during EAE. On day 25 postimmunization with MOG<sub>35-55</sub>, Mir155<sup>−/−</sup> mice had substantially diminished amounts of Th17 cells in both their LNs and spleens compared to WT mice (Figures 2A and 2B). Moderately reduced amounts of IFN-γ-producing Th1 CD4<sup>+</sup> cells were also found in the spleens but not LNs of MOG<sub>35-55</sub>-immunized mice in the absence of miR-155 (Figures 2A and 2B). The total numbers of these inflammatory T cell populations in the spleen and LNs were also similarly reduced in Mir155<sup>−/−</sup> versus Mir155<sup>+/+</sup> mice 25 days after immunization with MOG<sub>35-55</sub> (Figure S2).

The in vitro recall response to the MOG<sub>35-55</sub> peptide by WT and Mir155<sup>−/−</sup> CD4<sup>+</sup> T cells from the spleens of EAE mice was also assessed. Carboxyfluorescein succinimidyl ester (CFSE)-labeled splenocytes from day 25 EAE mice were restimulated in vitro with 20 μg/ml of MOG<sub>35-55</sub> or cultured in medium alone for 72 hr followed by flow cytometric analysis to determine the extent of CD4<sup>+</sup> proliferation as determined by dilution of CFSE. We found that WT CD4<sup>+</sup> T cells underwent cell divisions after exposure to MOG<sub>35-55</sub>, whereas Mir155<sup>−/−</sup> CD4<sup>+</sup> T cells had a substantially reduced proliferative response to the same peptide (Figure 2C). In parallel, [3H] thymidine incorporation assays via total splenocytes produced similar differences (Figure 2D). Tissue culture supernatants from these experiments were assayed for IL-17A and IFN-γ production by ELISA in response to MOG<sub>35-55</sub> stimulation. MOG<sub>35-55</sub>-stimulated Mir155<sup>−/−</sup> splenocytes showed minimal production of both of these cytokines compared to WT splenocytes, further demonstrating a defective CD4<sup>+</sup> T cell-driven recall response to antigen (Figure 2E).

We next investigated whether a defect in inflammatory T cell development could also be detected during the initial onset, or induction phase, of EAE. Mice were harvested on day 13 postimmunization with MOG<sub>35-55</sub> and the LNs from Mir155<sup>−/−</sup> mice had reduced numbers of live cells compared to WT controls, whereas the brains (CNS) and spleens from the two groups had similar total cell numbers (Figure S3). Inflammatory T cell development in the brains, LNs, and spleens was next assessed. Mir155<sup>−/−</sup> mice had substantial reductions in both the absolute numbers of Th17 cells and the percentage of Th17 cells among total CD4<sup>+</sup> T cells in their brains compared to Mir155<sup>+/+</sup> control mice (Figures 3A and 3B). IFN-γ-producing Th1 cells were present at lower absolute numbers in the brains of Mir155<sup>−/−</sup> mice, whereas the proportion of Th1 cells among total CD4<sup>+</sup> T cells was equivalent between Mir155<sup>−/−</sup> and Mir155<sup>+/+</sup> brains (Figure 3B). BIC (the noncoding RNA that gives rise to miR-155) expression was detected by quantitative PCR (qPCR) in Mir155<sup>+/+</sup> but not Mir155<sup>−/−</sup> splenocytes, and deficiencies in both IL-17A and IL-23 p19 mRNAs were also observed (Figure 3C). Intracellular staining revealed diminished numbers of Th17 and Th1 CD4<sup>+</sup> T cells in Mir155<sup>−/−</sup> spleens (Figure 3D). The recall response to MOG<sub>35-55</sub> was also tested with splenocytes from day 13 EAE mice.
Mir155–/– splenocytes exhibited diminished proliferation during this assay (Figure 3E). Defective production of IL-17A, IFN-γ, IL-6, and granulocyte-monocyte-colony-stimulating factor (GM-CSF) by MOG35-55 restimulated Mir155–/– encephalitogenic splenocytes was evident (Figure 3F). Similar deficiencies in Th1 and Th17 cells were also observed in the LNs from Mir155–/–
mice at this same time point (Figure 3G and 3H). These data indicate that the development of inflammatory T cells in Mir155−/− mice is defective during the early, induction phase of EAE.

A recent report found reduced numbers of T regulatory cells in Mir155−/− mice under steady-state conditions (Kohlhaas et al., 2009; Lu et al., 2009). Consistent with these
findings, we also observed lower Treg cell amounts in both the LN and spleens of \(\text{Mir}155^{-/-}\) mice compared to WT controls during EAE (Figure S2). However, \(\text{Mir}155^{-/-}\) Treg cells are not functionally defective compared to WT Treg cells on a per cell basis (Kohlhaas et al., 2009; Lu et al., 2009). Thus, the reduced EAE inflammation in \(\text{Mir}155^{-/-}\) mice...
seems unlikely to be related to the Treg cell population in these animals.

Also in agreement with earlier studies (Rodriguez et al., 2007; Thai et al., 2007; Vigorito et al., 2007), we found reduced titers of anti-MOG35-55 IgG antibodies in Mir155−/− mice during EAE (Figure S2). It has been reported that B cells, and therefore antibodies, are dispensable specifically for MOG35-55-driven EAE (Hjelmström et al., 1998), so it is likely that the observed antibody deficit does not account for the reduced disease severity seen in Mir155−/− mice.

**Mir155−/− Mice Have Reduced Foot Pad Inflammation during Delayed Type Hypersensitivity**

Another Th17 cell-dependent model of inflammation was next used to assess whether Mir155−/− mice have a general deficit in mediating inflammatory responses to specific antigens (Ghiardini et al., 2004). WT and Mir155−/− mice were immunized with keyhole limpet hemocyanin (KLH) in complete Freund’s adjuvant (CFA), and 8 days later challenged in one footpad with KLH and in the contralateral footpad with saline. After 48 hr, footpad thickness was measured to assess the delayed type hypersensitivity (DTH) response. As expected, WT mice had a substantial increase in footpad inflammation after KLH administration compared to saline alone (Figure 4A). In contrast, Mir155−/− mice exhibited reduced amounts of swelling in response to KLH as compared to WT mice (Figure 4A). Splenocytes and LN cells were also harvested on day 10, and Mir155−/− LN and LN cells had significantly fewer total cells than WT controls, consistent with a blunted inflammatory response (Figure 4B). Cells from both organs were restimulated with KLH for 3 days. Although LN cell and splenocyte proliferative differences were not observed in response to stimulation with KLH (Figure 4C), substantial reductions in IL-17A, IFN-γ, and IL-6 production were seen in Mir155−/− versus WT splenocytes and LN cells during recall responses (Figure 4D). These data support a general role for miR-155 in mediating antigen- and tissue-specific inflammation and point to a consistent defect in inflammatory T cell production.

---

**Figure 4.** Mir155−/− Mice Have Reduced Foot Pad Inflammation during DTH

Mir155−/− and Mir155+/+ mice were immunized with 100 µg of KLH in CFA and 8 days later injected with 50 µg of KLH in one footpad and PBS in the other. (A) Increases in footpad inflammation were measured for both groups (n = 5). (B) Total numbers of splenocytes and LN cells were assessed (n = 5). (C) Proliferation of splenocytes and LN cells after in vitro restimulation with KLH was determined by assaying [3H] thymidine incorporation (n = 5). (D) Production of IL-17A, IFN-γ, and IL-6 from the cells in (C) was determined by ELISA (n = 5). Error bars represent ±SEM and asterisk denotes statistical significance with a p value of < 0.05 according to a Student’s t test. +/+ = Mir155+/+; −/− = Mir155−/−.
miRNA-155 Promotes Autoimmune Inflammation

A T Cell-Intrinsic Role for miR-155 in the Development of Inflammatory T Cells during EAE

Inflammatory T cells must be able to properly receive and coordinate the signals provided by specific inflammatory cytokines that mediate their development. Therefore, we tested whether miR-155 expression by CD4+ T cells is involved in their ability to be skewed toward the Th17 cell lineage in vitro. CD4+ splenic T cells were isolated from Mir155++/+ and Mir155−/− mice and cultured in the presence of CD3 and CD28 antibodies with and without the addition of the Th17 cell skewing factors IL-6 and TGF-β. After 4 days of culture, we found that Mir155−/− CD4+ T cells were defective in their ability to produce Th17 cells compared to WT controls as assayed by intracellular staining of IL-17A (Figures 5A and 5B). The same cell populations and culture conditions produced similar amounts of IFN-γ+ Th1 cells despite the miR-155 deficiency (Figures 5A and 5B). As in previous reports (Haasch et al., 2002), we also observed upregulation of miR-155 in activated CD4+ T cells (Figure 5C), and we detected expression of BIC and miR-155 in CD4+ T cells grown in conditions that promote Th17 cell development (Figure 5D).

Reduced expression of IL-17A mRNA was measured in Mir155−/− compared to WT CD4+ T cells under Th17 cell skewing conditions (Figure 5D). These results reveal a T cell-intrinsic role for miR-155 in promoting the in vitro development of Th17 cells.

To test whether miR-155 plays a T cell-intrinsic role in driving inflammatory T cell development during EAE in mice, we adoptively transferred 1 × 10⁷ naïve CD45.1+CD4+ T cells into both WT and Mir155−/− recipients and induced EAE 24 hr later. Although Mir155−/− mice began to show clinical symptoms a few days before Mir155−/− mice, both groups exhibited similar disease scores for most of the time course (Figure 6D). The brain was harvested on day 23 postimmunization, and the development of Th17 and Th1 cells was determined by intracellular staining for IL17A and IFN-γ, respectively (Figures 6E and 6F; Figure S4). Although both mouse groups had roughly equivalent percentages of both Th17 and Th1 cells among the total CD4+ T cells in the brain, these cellular subsets were comprised predominately of the adoptively transferred CD45.1+CD4+ WT T cells in the CNS of Mir155−/− mice. This bias occurred despite roughly similar amounts of both WT and Mir155−/− CD4+ T cells in the brains of both mouse groups (Figures 6E and 6F). Conversely, these same inflammatory T cell populations were comprised largely of endogenous origin (CD45.2+CD4+ Mir155+/+ T cells) in the CNS of Mir155+/+ mice (Figures 6E and 6F). These data demonstrate that miR-155 expression by CD4+ T cells is critical for the proper development of inflammatory T cell subsets in the CNS and that this accounts for a majority of miR-155’s contribution to EAE.

miR-155 Expression Is Necessary for Proper Secretion of Th17 Cell-Related Inflammatory Cytokines by DCs

Because of the lag in EAE phenotype development when WT CD4+ T cells were administered to Mir155−/− mice, it is possible that miR-155 also functions in non-T cell immune cell types to promote inflammatory T cell development. For encephalitogenic
Figure 6. Expression of miR-155 by CD4+ T Cells Is Required for Proper Development of Inflammatory T Cells during EAE

(A) $5 \times 10^6$ WT or Mir155$^{-/-}$ CD4+ T cells from naive mice were injected i.v. into Rag1$^{-/-}$ recipients, EAE was induced with MOG$_{35-55}$ 24 hr later, and disease was scored over a time course (n = 5–6). Data represent two independent experiments.

(B) Mice were harvested and engraftment of CD3+CD4+ T cells was assayed by flow cytometry with splenocytes (top). Expression of IL-17A and IFN-γ by CD4+ cells in the spleens and LNs was assayed by intracellular staining followed by flow cytometry. A representative plot from the LNs is shown (bottom).

(C) The averages of 5–6 mice per group are shown graphically.

(D) Mir155$^{+/+}$ and Mir155$^{-/-}$ mice were injected with $1 \times 10^7$ WT CD45.1+CD4+ naive T cells, and EAE was induced 24 hr later (n = 5). Disease symptoms were scored over a time course. Data represent two independent experiments.

(E) Mice were harvested and CD4+ T cells in the brains were analyzed by flow cytometry to detect cells expressing CD45.1, IL-17A, and IFN-γ.

(F) The average of five mice per group from (E).

Error bars represent ±SEM and asterisk denotes statistical significance with a p value of < 0.05 according to a Student’s two-tailed t test. $+/+$ = Mir155$^{+/+}$; $-/-$ = Mir155$^{-/-}$. See also Figure S4.
Th17 cells to develop, they must receive signals from relevant inflammatory cytokines, such as IL-6 and IL-23, which are produced by GM-CSF-derived DCs (Gutcher and Becher, 2007). Therefore, we examined the impact of miR-155 on the gene expression profile of LPS-activated DCs, which express high levels of miR-155 (Figures 7A and 7B). Total RNA was collected from purified WT or Mir155<−/−> DCs after 20 hr of LPS treatment and subjected to a microarray analysis. Several targets of miR-155 were expressed at higher amounts in Mir155<−/−> versus WT control DCs (Figure 7C). Among these, SHIP1 and SOCS1 have been shown to be directly targeted by miR-155 (Androulidaki et al., 2009; Lu et al., 2009; O’Connell et al., 2009) and to function by negatively regulating cytokine production by DCs (An et al., 2005; Shen et al., 2004). Their elevated expression in Mir155<−/−> DCs was confirmed via quantitative PCR (qPCR) and by immunoblotting (Figure 7D). Consistent with the elevated expression of these negative regulators, decreased expression of several inflammatory cytokine genes including IL-6, IL-23 p19, and IL-12 and IL-23 p40 was observed in Mir155<−/−> DCs (Figure 7C). These results were confirmed by qPCR and ELISA, which also detected a subtle decrease in tumor necrosis factor-α (TNF-α) production (Figures 7E and 7F). To further corroborate these findings, miR-155 was overexpressed in GM-CSF-derived DCs via a retroviral vector described previously (O’Connell et al., 2009), and higher amounts of IL-6, IL-23 p19, IL-12 and IL-23 p40, and TNF-α mRNA expression were observed after LPS treatment (Figure 7G). We also tested whether Mir155<+/−> DCs were defective in their ability to induce CD4<sup>+</sup> T cell proliferation after presentation of cognate antigens. Both Mir155<+/−> and Mir155<−/−> DCs induced equivalent proliferation of 2D2 or OT2 CD4<sup>+</sup> T cells that recognize MOG<sub>35-55</sub> or an ovalbumin peptide, respectively (Figure 7H). Taken together, these experiments demonstrate that miR-155 promotes DC expression of specific cytokines required for inflammatory T cell development.

**DISCUSSION**

We have shown here that miR-155 plays an important role in driving chronic inflammation that is inappropriately directed at tissue-specific antigens, a destructive process that is at the heart of human autoimmune diseases. At the cellular level, Mir155<−/−> mice exhibit defective inflammatory T cell development during the induction phase of autoimmunity. This appears to be largely due to miR-155 function in CD4<sup>+</sup> T cells, and may also involve insufficient production of inflammatory cytokines by DCs. Although diminished inflammatory T cell development is beneficial in the context of autoimmunity, it is detrimental to mammals after infection by certain pathogens. Thus, our observations also suggest a protective role for miR-155 in response to infection.

miR-155 expression is dramatically increased in CD4<sup>+</sup> T cells upon their activation, suggesting functional importance for this miRNA in activated T cells (Haasch et al., 2002). Our results expand upon previous work, which demonstrated that miR-155 can impact Th1 cell and Th2 cell lineage skewing in vitro (Rodriguez et al., 2007; Thai et al., 2007), by finding a role for miR-155 in Th17 cell biology both in vitro and in vivo. Recently, inhibition of miR-326 via a miRNA “sponge” was shown to reduce EAE symptoms by preventing Th17 cell differentiation also through a T cell-intrinsic mechanism (Du et al., 2009). Thus, multiple miRNAs appear to directly regulate inflammatory T cell development, as suggested by early studies analyzing Dicer-deficient T cells (Muljo et al., 2005).

Many direct targets of miR-155 in CD4<sup>+</sup> T cells have been identified, some of which impact Th cell lineage decisions (Rodriguez et al., 2007). For instance, c-Maf is targeted by miR-155 and functions as a promoter of Th2 cell development (Rodriguez et al., 2007), while SOCS1 is repressed by miR-155 in both FoxP3<sup>+</sup>CD4<sup>+</sup> Treg cells and FoxP3<sup>−/−</sup> T cells and impacts Treg cell fitness (Lu et al., 2009). In general, a complex picture of how miR-155 directs T cell developmental pathways is emerging and it appears to involve many targets and pathways. This may also be true for miR-155’s positive role in Th17 cell development. On one hand, miR-155 might function to block the inhibitory impact of cytokines such as IL-4 and IFN-γ on the Th17 cell differentiation pathway. miR-155 has been shown to limit production of IL-4 by CD4<sup>+</sup> T cells through repression of c-Maf (Rodriguez et al., 2007), while IFN-γ-R mRNA is directly targeted by miR-155 in CD4<sup>+</sup> T cells (Banerjee et al., 2010). However, we found that WT CD4<sup>+</sup> T cells restore EAE disease severity following their adoptive transfer into Mir155<−/−> mice. This argues against a major role for elevated production of a secreted inhibitory molecule like IL-4 being responsible for the reduced EAE observed in Mir155<−/−> mice because it would also inhibit the transferred WT T cells through a paracrine mechanism.

Alternatively, it is possible that miR-155 can positively regulate signaling pathways that promote Th17 cell formation. This could be achieved via repression of proteins that function to negatively regulate signaling pathways that are activated by TGF-β, IL-6, and IL-23. Although it is unclear whether miR-155 directly regulates these pathways in CD4<sup>+</sup> T cells, recent studies found that miR-155 targets Sma- and Mad-related protein 5 (Smad5) in B cell lymphoma cells (Rai et al., 2010) and activates signal transducer and activator of transcription 3 (Stat3) in breast cancer cells (Jiang et al., 2010), factors involved in TGF-β and IL-6 signaling, respectively. Moving forward, the identity and relative importance of each target of miR-155 during the development of different T cell lineages, including Th17 cells, should continue to be investigated, and may reveal a differential importance for unique targets of miR-155 depending on the T cell subset.

Interestingly, a previous study found that Mir155<−/−> FoxP3<sup>+</sup> CD4<sup>+</sup> T cells were at a competitive disadvantage in the presence of WT FoxP3<sup>+</sup> CD4<sup>+</sup> T cells under steady-state conditions (Lu et al., 2009). During our EAE phenotype “rescue” experiments, Mir155<−/−> CD4<sup>+</sup> T cells also showed reduced fitness compared to the adoptively transferred WT CD4<sup>+</sup> T cells. Thus, the role of miR-155 in conferring CD4<sup>+</sup> T cell fitness extends to inflammatory settings where miR-155 is also required for proper inflammatory T cell differentiation. These reductions in fitness and differentiation by effector T cells may explain why Mir155<−/−> mice do not succumb to spontaneous systemic autoimmunity or suffer from heightened EAE symptoms as a consequence of their reduced Treg cell numbers (Lu et al., 2009).

Similar to Mir155<−/−> mice, GM-CSF-deficient mice are also resistant to EAE (McQualter et al., 2001) and GM-CSF-derived DCs have recently been linked to Th17 cell development during autoimmunity by functioning as an important source of the Th17 cytokines IL-6 and IL-23 (Sonderegger et al., 2008). Our present
Figure 7. miR-155 Expression by LPS-Activated, GM-CSF-Derived Myeloid Dendritic Cells Is Necessary for Proper Production of Th17 Cell-Relevant Inflammatory Cytokines

(A) CD11c+ DCs were derived with GM-CSF at 20 ng/ml.
(B) Expression of BIC (top) and mature miR-155 (bottom) before and after 20 hr of LPS stimulation (100 ng/ml) was assayed via qPCR.
(C) Total RNA was next used for a microarray analysis to determine mRNA expression differences between Mir155+/+ and Mir155−/− LPS-treated DCs. Several selected targets of miR-155 were expressed in higher amounts in Mir155−/− DCs, while a subset of selected proinflammatory cytokines were expressed at lower amounts. Red, higher expression; green, lower expression in the Mir155−/− versus Mir155+/+ DCs.
(D) Expression of SHIP1 and SOCS1 mRNAs was assessed by qPCR and by immunoblotting (n = 3).
(E) qPCR was also used to assay expression of IL-23 p19, IL-6, IL-12 and IL-23 p40, and TNF-α mRNA amounts (n = 3). Data represent two independent experiments.
(F) Concentrations of the cytokines from (E) in the culture supernatants were determined by ELISAs (n = 3). Data represent two independent experiments.
(G) GM-CSF-derived DCs overexpressing miR-155, a miR-155 “seed” mutant, or a control vector were stimulated with LPS for 20 hr and expression of IL-23 p19, IL-6, IL-12 and IL-23 p40, and TNF-α mRNA was assayed by qPCR. Data represent two independent experiments.
(H) Proliferation of 2D2 or OT2 CD4+ T cells in response to their respective antigens presented by WT or Mir155−/− DCs was assessed by assaying 3[H] thymidine incorporation (n = 3). Data represent two independent experiments.

Error bars represent ±SEM and asterisk denotes statistical significance with a p value of < 0.05 according to a Student’s two-tailed t test.
work demonstrates that miR-155 is upregulated in GM-CSF-derived DCs and functions to enhance production of these cytokines. This may contribute to the defects in Th17 cell development and tissue-specific inflammation observed in the Mir155−/− mice. Additionally, because Th17 cells are a primary source of GM-CSF during EAE (Ponomarev et al., 2007), they are thought to reinforce this chronic inflammatory condition by generating additional DCs. Thus, the defective production of Th17 cells in Mir155−/− mice during EAE may also explain the reduced amounts of GM-CSF observed during our splenocyte recall response experiments. Together, our data suggest a role for miR-155 in regulating both the production and function of GM-CSF-derived DCs in the promotion of autoimmune inflammation.

Elevated expression of miR-155 has been observed in brain lesions from multiple sclerosis (MS) patients (Junker et al., 2009) and in synovial samples from patients with rheumatoid arthritis (RA) (Stanczyk et al., 2008). Human trials have found that inhibition of the IL-23–IL-17 inflammatory axis via blocking antibodies can reduce the severity of psoriasis and rheumatoid arthritis (Steinman, 2010). Based upon this expression profile and our current study, miR-155 may be an effective therapeutic target in the treatment of a range of autoimmune conditions where Th17 cells have been shown to drive disease. However, delivery of miRNA inhibitors to specific cell types in vivo remains a difficult challenge.

In addition to inflammatory T cells, many autoimmune conditions, including human MS, RA, and systemic lupus erythematosus (SLE), also involve the actions of auto-antibodies that have been shown to exacerbate these diseases. Beyond its role in mediating inflammatory T cell development as identified in our current study, previous reports have clearly shown that miR-155 is important for production of antigen-specific IgGs (Rodriguez et al., 2007; Thai et al., 2007; Vigorito et al., 2007). Therefore, modulation of miR-155 may be able to treat conditions that depend both upon humoral and cell-mediated immune mechanisms, making it a versatile therapeutic target.

**EXPERIMENTAL PROCEDURES**

**Mice**

All experiments were approved by the Caltech Institutional Animal Care and Use Committee (IACUC). Mir155+/+, Mir155−/−, Rag1−/−, CD45.1+, OT2, and CD45.1− mice were all on a C57BL/6 genetic background. For bone marrow reconstitution, mice were conditioned with 1000 Rads via a Cs137 source prior to injection of donor BM.

**Mouse Models of EAE and DTH**

For induction of EAE, mice were injected subcutaneously (s.c.) into the base of the tail with a volume of 200 μl containing 100 μg/ml MOG35-55 peptide (GenScript) emulsified in complete Freund’s adjuvant (CFA). Mice were also injected intraperitoneally (i.p.) with 200 ng of pertussis toxin on days 0 and 2, and clinical symptoms were scored regularly according to the following criteria: 0, no symptoms; 0.5, partially limp tail; 1, completely limp tail; 1.5, impaired righting reflex; 2, hind limb paresis; 2.5, hind-limb paralysis; 3, forelimb weakness; 4, complete paralysis; 5, death. For induction of DTH responses, keyhole limpet hemocyanin (KLH) was purchased from Calbiochem. Mice were immunized s.c. at the base of the tail with 100 μg KLH in 200 μl CFA. To assess DTH, all mice involved in the studies were given 50 μl KLH in 50 μl PBS intradermally into the left foot pad and 50 μl phosphate buffered saline (PBS) alone in the right foot pad 8 days after the immunization. 2 days later, foot pad swelling was measured.

**Cell Culture and Reagents**

DCs were derived from WT or Mir155−/− RBC-depleted bone marrow via rGM-CSF (ebioscience) at a concentration of 20 ng/ml in complete RPMI (supplemented with 10% FBS, 100 units/ml penicillin, 100 units/ml streptomycin, 50 μM beta-mercaptoethanol). Cells were cultured at 5% CO2 and 37°C in a humified incubator. DCs were stimulated with E. coli LPS (Sigma) at a concentration of 100 ng/ml. For Th17 cell skewing, CD4+ splenocytes were cultured in complete RPMI, plate-bound CD3 antibodies, and soluble CD28 antibodies (2 μg/ml), IL-6 (50 ng/ml), and TGF-β (2 ng/ml) (Biologend) for 96 hr. Splenocytes or LN cells were also cultured in complete RPMI during restimulation with relevant antigens. The MOG35-55 peptide was synthesized by GenScript. KLH was obtained from Calbiochem. For CFSE experiments, 25 × 106 splenocytes were labeled in 5 μM CFSE for 10 min at 37°C, washed, and cultured. Cellular proliferation was also assessed by pulsing cells with ^3H thymidine (1 μCi/well) for the final 18 hr. For coculture assays, WT or Mir155−/− DCs were pulsed with the MOG35-55 peptide or Ovalbumin and used to activate purified 2D2 or OT2 CD4+ T cells, respectively, at a 1:10 ratio. For some experiments, splenocytes were obtained from day 12 EAE WT mice and cultured with 20 μg/ml MOG35-55 and 20 ng/ml IL-12 for 2 days before cells were washed and injected intravenously.

**Intracellular Staining and Flow Cytometry**

To detect intracellular expression of IL-17A, IFN-γ, or FoxP3 in CD4+ splenocytes, CD45.1+ mice were scored (purified with Percoll) were first treated with 750 ng/ml ionomycin and 50 ng/ml phorbol myristate acetate (PMA) (Calbiochem) in the presence of 0.5 μl of GolgiPlug (BD Biosciences) for 4–5 hr at 37°C. Cells were subsequently surface stained with CD4+ antibodies and then permeabilized and fixed in 100 μl of eBioscience Perm-Fix solution overnight at 4°C. Cells were washed once in perm wash buffer (eBioscience) and then stained with 0.3 μg of fluorophore-conjugated anti-IL-17A, IFN-γ, or FoxP3 (eBioscience) for 20 min at 4°C. Fluorophore-conjugated monoclonal antibodies specific to CD11b (Mac1), CD3ε, or B220 (eBioscience) were used to stain red blood cell (RBC)-lysed splenocytes or LN cells. Antibodies recognizing CD11c (eBioscience) were also used to stain in vitro derived DCs. After washing, stained cells were assayed with a BD FACSCalibur flow cytometer and results further processed with FlowJo software.

**Microarray and qPCR**

Total RNA was isolated from magnetic-activated cell separation (MACS)-sorted, LPS-activated CD11c+ myeloid DCs derived from WT or Mir155−/− BM via Trizol (Invitrogen) per manufacturer’s instructions. Global mRNA expression amounts were next assessed with the Affymetrix total mouse genome array V 2.0 as described previously (O’Connell et al., 2008), and the data were analyzed further with Rosetta Resolver software. Sybrgreen-based quantitative real-time PCR (qPCR) was conducted with the 7300 Realtime PCR system (Applied Biosystems, Foster City, CA) to assay BIC, SHIP1, SOCS1, IL-17A, IL-6, IL-23 p19, IL-12 and IL-23 p40, TNF-α, and L32 mRNA amounts with gene-specific primers (sequences available upon request). Mature miR-155 and sno202 RNA amounts were assessed with specific Taqman probes from Applied Biosystems. For all experiments, miRNA was normalized to L32 and miRNA to sno202.

**ELISAs**

To detect protein expression of GM-CSF, IL-6, IL-17A, IFN-γ, IL-23 p19 and p40, IL-12 and IL-23 p40, and TNF-α, ELISAs were performed with cytokine-specific kits from eBioscience and carried out according to the manufacturer’s instructions. Serum IgG antibodies against MOG35-55 were assayed by plating serial dilutions of mouse serum on plates coated with MOG35-55 and bound antibodies detected with biotinylated anti-mouse IgG antibodies and Streptavidin horseradish peroxidase (HRP) (Southern Biotech).

**Immunoblotting**

Cellular extract was size fractionated via sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting was performed in accordance with standard protocols. Specific antibodies were used to detect SHIP1, SOCS1, and β-actin.
Retrovirus Production and Infections
Murine stem cell virus (MSCV)-based retroviruses expressing murine miR-155 were prepared as described previously (O’Connell et al., 2009) and used to spin infect freshly isolated WT bone marrow. Immediately following, cells were cultured in GM-CSF containing medium until day 7 before LPS stimulation.

Histological Examination of Central Nervous System Tissues
Brains and spinal cords from EAE mice were dissected and fixed in formaldehyde for 48 hr. Tissue sections were next prepared, stained with H&E, and visualized with a Nikon Eclipse 50i microscope, and photographed with a Spot digital camera. Sections were scored by a pathologist blinded to the genotype of the tissue or the clinical severity of disease according to the following criteria: 0, no sign of infiltrate; 1, perivascular congestion (light); 2, perivascular congestion (heavy); 3, perivascular congestion (heavy) and parenchymal infiltrate; 4, focal meningeal lymphocytosis; 5, extensive sclerosis.

Statistical Analysis
Statistical significance was determined by performing a two-tailed t test. p values < 0.05 were considered significant.

ACCESSION NUMBERS
The microarray data are available in the Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geo/) under the accession number GSE23641.

SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and can be found with this article online at doi:10.1016/j.immuni.2010.09.009.

ACKNOWLEDGMENTS
R.M.O. was funded in part by the Irvington Institute Fellowship Program of the Cancer Research Institute and by award number K99HL102228 from the National Heart, Lung and Blood Institute. D.K. was supported by the National Institutes of Health—Building Interdisciplinary Research Careers in Women’s Health (BIRCWH) center at UCLA (K12 HD001400). A.A.C. was funded by the Graduate Research Fellowship Program of the National Science Foundation. D.S.R. was funded by award number 1K08CA133521 from the National Cancer Institute. J.L.R. is a Merck Fellow of the Jane Coffin Child’s Memorial Fund. This work was also supported by NIH grant 1R01AI079243-01. We would like to thank A. Bradley for providing us with Mir155−/− mice. E.D. is a scientific advisor to Regulus Therapeutics, a company devoted to microRNA therapeutics.

Received: April 5, 2010
Revised: July 19, 2010
Accepted: September 13, 2010
Published online: September 30, 2010

REFERENCES
Immunity

miRNA-155 Promotes Autoimmune Inflammation


